Heterogeneity and Hierarchy of Immune Response to Primary Immunization in HIV-Infected Children on HAART and the Impact of an Additional Dose of Vaccine
- PMID: 38801497
- DOI: 10.1007/s12098-024-05148-4
Heterogeneity and Hierarchy of Immune Response to Primary Immunization in HIV-Infected Children on HAART and the Impact of an Additional Dose of Vaccine
Abstract
The nature of vaccine response inferiority is not well studied in children living with HIV (CLHIV). The authors investigated Hepatitis B Virus (HBV) and Diphtheria/Pertussis/Tetanus toxoid (DPT) vaccination responses following primary immunization in CLHIV (n = 42) and healthy controls (HC) (n = 38) and the effect of an additional vaccine dose. Antibody responses, CD4 and HBV-specific T/B cells were analysed using CMIA/ELISA and flow-cytometry. CLHIV had significantly lower baseline median antibody titres for all vaccines than HC (p <0.02). Differential seroprotection rates observed in CLHIV were, 4.8% for pertussis; 9.5% for HBV; 26.2% for diphtheria and 66.7% for tetanus. WHO staging significantly influenced anti-HBs levels (p = 0.0095). HBsAg-specific CD4+T-cells were significantly higher in CLHIV than HC (p = 0.042). An additional vaccine dose (HBV and Tdap) conferred a higher protection rate for tetanus and diphtheria (p <0.040) in CLHIV. These findings suggest that CLHIV exhibit a hierarchy of vaccine responses affecting antibody levels and protection rate, which was rescued by administering additional vaccine dose.
Keywords: Children; HIV; Hepatitis B; India; Tdap; Vaccine.
© 2024. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Conflict of interest statement
Declarations. Conflict of Interest: None.
Similar articles
-
Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy.AIDS. 2014 Feb 20;28(4):531-41. doi: 10.1097/QAD.0000000000000127. AIDS. 2014. PMID: 24468996 Clinical Trial.
-
Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.Expert Rev Vaccines. 2019 Jan;18(1):95-104. doi: 10.1080/14760584.2019.1547195. Epub 2018 Nov 19. Expert Rev Vaccines. 2019. PMID: 30417710 Free PMC article. Clinical Trial.
-
Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.Hum Vaccin Immunother. 2019;15(4):809-821. doi: 10.1080/21645515.2018.1549449. Epub 2019 Jan 4. Hum Vaccin Immunother. 2019. PMID: 30444673 Free PMC article. Clinical Trial.
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.Vaccine. 2018 Feb 8;36(7):986-996. doi: 10.1016/j.vaccine.2018.01.005. Epub 2018 Jan 12. Vaccine. 2018. PMID: 29336924 Review.
References
-
- UNAIDS. Global HIV and AIDS Statistics - Factsheet. [Internet]. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_... .
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials